Cited by 41MRI in cancer diagnosisHepatocellular Carcinoma Treatment and PrognosisMedical Imaging Techniques and Applications

Gadoxetate acid-enhanced MR imaging for HCC: A review for clinicians

Open access
Chanyaputhipong, Jendana, Low, Su-Chong Albert, Chow, Pierce K. H.·2011·International Journal of Hepatology

Abstract

Hepatocellular carcinoma (HCC) is increasingly being detected at an earlier stage, owing to the screening programs and regular imaging follow-up in high-risk populations. Small HCCs still pose diagnostic challenges on imaging due to decreased sensitivity and increased frequency of atypical features. Differentiating early HCC from premalignant or benign nodules is important as management differs and has implications on both the quality of life and the overall survival for the patients. Gadoxetate acid (Gd-EOB-DTPA, Primovist(®), Bayer Schering Pharma) is a relatively new, safe and well-tolerated liver-specific contrast agent for magnetic resonance (MR) imaging of the liver that has combined perfusion- and hepatocyte-specific properties, allowing for the acquisition of both dynamic and hepatobiliary phase images. Its high biliary uptake and excretion improves lesion detection and characterization by increasing liver-to-lesion conspicuity in the added hepatobiliary phase imaging. To date, gadoxetate acid-enhanced MRI has been mostly shown to be superior to unenhanced MRI, computed tomography, and other types of contrast agents in the detection and characterization of liver lesions. This review article focuses on the evolving role of gadoxetate acid in the characterization of HCC, differentiating it from other mimickers of HCC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4061/2011/489342

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In case of high amounts of macrophages present in the lesion, a condition often observed in well-differentiated HCC, SPION will not allow for accurate discrimination between malignant and benign liver lesions.

    “Furthermore, in case of high amounts of macrophages present in the lesion, a condition often observed in well-differentiated HCC, SPION will not allow for accurate discrimination between malignant and benign liver lesions.”
  • Primovist shows superiority in HCC detection due to specific uptake by hepatocytes instead of macrophages.

    “Conversely, in such situations, Primovist® shows superiority in HCC detection, due to specific uptake by hepatocytes instead of macrophages [151].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [98]Blondin D Erhardt A Crynen K Diagnosis of focal liver lesions in cirrhotic patients: comparison of contrast-enhanced ultrasound using sulphur hexafluoride (SF6) microbubbles and MRI using Gd-EOB-DTPA Zeitschrift für Gastroenterologie 2011 49 1 23 29 21225534

Cited by

Sorted by citations

Authors
Chanyaputhipong, J., Low, S.-C. A., & Chow, P. K. H.
Affiliations
  • Singapore General Hospital (SG)
  • National University of Singapore (SG)
Corresponding author
Low, Su-Chong Albert
Venue
International Journal of Hepatology
Publisher
Wiley
Published
2011
Volume
2011
Pages
1-13
ISSN
  • 2090-3448 (ISSN-L)
  • 2090-3456
OpenAlex
W1991749949
Cited by
41
References
98
Citations by year
2025: 1 · 2023: 3 · 2021: 2 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 7 · 2014: 4 · 2013: 5 · 2012: 2
FWCI
2.69
Type
journal article
Language
en
Open access
Locations
  • International Journal of Hepatology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
hepatocellular carcinoma, hepatobiliary phase imaging, liver-specific contrast agents, differential diagnosis of liver nodules, liver MRI

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review